文献速递乳腺MR

超快动态对比增强乳腺MRI:与新辅助治疗中乳腺癌病理完全缓解的相关性

Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
PubMed 文献 · Eur Radiol · 2022-01-22

研究纳入2018年8月至2019年6月间256例连续乳腺癌患者,评估治疗前超快DCE-MRI动力学特征与病理完全缓解(pCR)的关联。整体41.4%患者达到pCR,所有癌种中动力学特征均与pCR无关;在三阴性癌中,U1/U2体积比更高与pCR独立相关(多因素OR 14.811,p=0.005)。

要点

  • 三阴性乳腺癌中,超快DCE-MRI的U1/U2体积比更高与pCR独立相关(多因素OR 14.811,p=0.005)。
  • 激素受体阳性乳腺癌中,较低的最大斜率与pCR相关(单因素OR 0.982,p=0.040)。
  • 全部癌种混合分析时,超快DCE-MRI动力学特征均与pCR无关联。

核心结论

  • 超快DCE-MRI导出的U1/U2体积比更高在三阴性浸润性乳腺癌中与pCR独立相关;超快MRI有潜力提高预测治疗反应和个体化治疗的准确性。

研究设计与样本

  • 研究类型为连续纳入的回顾性分析,纳入2018年8月至2019年6月间256例接受新辅助化疗后手术的乳腺癌患者(平均年龄50.2岁,范围25-86岁),均行超快和常规DCE-MRI;参考标准为手术病理pCR。

诊断标准与关键数值

  • 整体pCR率为41.4%。
  • 三阴性癌中,U1/U2体积比更高与pCR相关:单因素分析OR 11.787(p=0.006),多因素分析OR 14.811(p=0.005)。
  • 激素受体阳性癌中,较低的最大斜率与pCR相关:单因素分析OR 0.982(p=0.040)。
  • 激素受体阳性癌中,常规DCE-MRI较低峰值强化(OR 0.993,p=0.031)和较低流出百分比(OR 0.904,p=0.039)与pCR相关(仅单因素分析)。

临床应用与阅片要点

  • 作者认为超快DCE-MRI有潜力提高预测治疗反应和个体化治疗的准确性。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study was to investigate whether pretreatment kinetic features from ultrafast DCE-MRI are associated with pathological complete response (pCR) in patients with invasive breast cancer and according to immunohistochemistry (IHC) subtype.

METHODS: Between August 2018 and June 2019, 256 consecutive breast cancer patients (mean age, 50.2 years; range, 25-86 years) who underwent both ultrafast and conventional DCE-MRI and surgery following neoadjuvant chemotherapy were included. DCE-MRI kinetic features were obtained from pretreatment MRI data. Time-to-enhancement, maximal slope (MS), and volumes at U1 and U2 (U1, time point at which the lesion starts to enhance; U2, subsequent time point after U1) were derived from ultrafast MRI. Logistic regression analysis was performed to identify factors associated with pCR.

RESULTS: Overall, 41.4% of all patients achieved pCR. None of the kinetic features was associated with pCR when including all cancers. Among ultrafast DCE-MRI kinetic features, a lower MS (OR, 0.982; p = 0.040) was associated with pCR at univariable analysis in hormone receptor (HR)-positive cancers. In triple-negative cancers, a higher volume ratio U1/U2 was associated with pCR at univariable (OR, 11.787; p = 0.006) and multivariable analysis (OR, 14.811; p = 0.005). Among conventional DCE-MRI kinetic features, a lower peak enhancement (OR, 0.993; p = 0.031) and a lower percentage of washout (OR, 0.904; p = 0.039) was associated with pCR only in HR-positive cancers at univariable analysis.

CONCLUSIONS: A higher volume ratio of U1/U2 derived from ultrafast DCE-MRI was independently associated with pCR in triple-negative invasive breast cancer.

KEY POINTS: • The ratio of tumor volumes obtained at the first (U1) and second time points (U2) of enhancement was independently associated with pCR in triple-negative invasive breast cancers. • Ultrafast MRI has the potential to improve accuracy in predicting treatment response and personalizing therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim, Park, Shin, et al. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer. Eur Radiol. 2022. PMID: 35064805. doi:10.1007/s00330-021-08530-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。